77.38 F
July 30, 2021

Biden administration to announce plan to ban menthol cigarettes, according to the Washington Post

WASHINGTON (Reuters) — The Biden administration this week is expected to propose a ban on menthol cigarettes, a move backed by civil rights groups that say Black Americans are hurt by the industry’s aggressive targeting of the product, the Washington Post reported on Wednesday.

The administration will seek to ban menthol and other flavors in mass-produced cigars, the newspaper reported, citing unidentified administration officials who spoke on condition of anonymity.

The U.S. Food and Drug Administration faces a Thursday court deadline to respond to a 2013 citizen’s petition seeking a ban on menthols. Public health groups filed a lawsuit last year in federal district court in Northern California to require the FDA to respond to the petition.

The Post said it could be years before any ban would take effect, but the move would be praised by anti-smoking groups. Tobacco use remains a leading source of preventable illness and death in the country, particularly for people of color.

“There is not an open question on whether menthol in cigarettes is harmful — the evidence is overwhelming and consistent,” Joelle Lester, director of commercial tobacco control programs at the Mitchell Hamline School of Law in Minnesota, told the Post.

The law center led a group of 19 public health organizations to file the 2013 petition.

The FDA was not immediately available for comment on the report.

(Reporting by Doina Chiacu and Carl O’Donnell; Editing by Tim Ahmann and Bill Berkrot)

© Copyright Thomson Reuters 2021


Related Stories

More stories you may be interested in

Related posts

Hot cars, dragging chains and dry grass make fiery combination


House passes sweeping voting rights bill over GOP opposition


Unified Fire Authority honors firefighters who died in the line of duty


Man arrested after police say he hid in manure charged in fatal auto-ped crash


Top U.S. Republicans promise peaceful transition after Trump sows doubts


US FDA staff backs Pfizer's coronavirus vaccine data